Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer

被引:43
|
作者
Honselmann, Kim C. [1 ,2 ,3 ]
Pergolini, Ilaria [1 ,2 ]
Fernandez-del Castillo, Carlos [1 ,2 ]
Deshpande, Vikram [1 ,2 ]
Ting, David [2 ,4 ]
Taylor, Martin S. [1 ,2 ]
Bolm, Louisa [3 ]
Qadan, Motaz [1 ,2 ]
Wellner, Ulrich [3 ]
Sandini, Marta [1 ,2 ]
Bausch, Dirk [3 ]
Warshaw, Andrew L. [1 ,2 ]
Lillemoe, Keith D. [1 ,2 ]
Keck, Tobias [3 ]
Ferrone, Cristina R. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Gastrointestinal Surg & Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Med Ctr Schleswig Holstein, Dept Surg, Campus Luebeck, Lubeck, Germany
[4] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA
关键词
lymph node status; PDAC; recurrence; survival; SHORT-COURSE CHEMORADIATION; PROTON-BEAM THERAPY; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; NEOADJUVANT TREATMENT; PANCREATICODUODENECTOMY; CAPECITABINE;
D O I
10.1097/SLA.0000000000003123
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Our aim was to evaluate recurrence patterns of surgically resected PDAC patients with negative (pN0) or positive (pN1) lymph nodes. Summary Background Data: Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. This is mostly due to early local and distant metastasis, even after surgical resection. Knowledge about patterns of recurrence in different patient populations could offer new therapeutic avenues. Methods: Clinicopathologic data were collected for 546 patients who underwent resection of their PDAC between 2005 and 2016 from 2 tertiary university centers. Patients were divided into an upfront resection group (n = 394) and a neoadjuvant group (n = 152). Results: Tumor recurrence was significantly less common in pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%,P< 0.001 and 64% vs. 78%,P= 0.040 in the neoadjuvant group). In addition, time to recurrence was significantly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN1P< 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1,P< 0.001). Of the patients who recurred, 62% presented with distant metastases (63% of pN0 and 62% of pN1,P= 0.553), 24% with local disease (27% of pN0 and 23% of pN1,P= 0.672) and 14% with synchronous local and distant disease (10% of pN0 and 15% of pN1,P= 0.292). Similarly, there was no difference in recurrence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant metastases (76% of pN0 and 64% of pN1,P= 0.326) and 18% recurred with local disease (pN0: 22% and pN1: 15%,P= 0.435). Conclusion: Time to recurrence was significantly longer for pN0 patients. However, patterns of recurrence for pN0 vs. pN1 patients were identical. Lymph node status was predictive of time to recurrence, but not location of recurrence.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 50 条
  • [21] PROGNOSTIC VALUE OF LYMPH NODE CHARACTERISTICS IN PATIENTS WITH NODE-POSITIVE OR NODE-NEGATIVE EARLY-STAGE CERVICAL CANCER
    Chong, G. O.
    Lee, Y. H.
    Lee, H. J.
    Hong, D. G.
    Lee, Y. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A205 - A205
  • [22] Dye-guided sentinel lymphadenectomy in clinically node-positive and node-negative breast cancer patients
    Noguchi, M
    Tsugawa, K
    Kawahara, F
    Bando, E
    Miwa, K
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S50 - S50
  • [23] Dye-guided sentinel lymphadenectomy in clinically node-negative and node-positive breast cancer patients
    Noguchi M.
    Tsugawa K.
    Kawahara F.
    Bando E.
    Miwa K.
    Minato H.
    Nonomura A.
    Breast Cancer, 1998, 5 (4) : 381 - 387
  • [24] Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients
    Trere, Davide
    Ceccarelli, Claudio
    Migaldi, Mario
    Santini, Donatella
    Taffurelli, Mario
    Tosti, Elena
    Chieco, Pasquale
    Derenzini, Massimo
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2006, 14 (03): : 314 - 323
  • [25] Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients
    Hutten, Ryan J.
    Parsons, Matthew W.
    Weil, Christopher R.
    Tward, Jonathan D.
    Lloyd, Shane
    Sanchez, Alejandro
    Lester-Coll, Nataniel
    Johnson, Skyler B.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : E360 - E366
  • [26] The number of resected axillary lymph nodes (ALN) influences the risk for axillary recurrences in node-positive, but not in node-negative patients.
    Janni, W
    Gerber, B
    Rack, B
    Strobl, B
    Rjosk, D
    Thieleke, W
    Sommer, H
    Friese, K
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S172 - S172
  • [27] Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients REPLY
    Morgan, Todd M.
    Cookson, Michael S.
    UROLOGY, 2012, 80 (03) : 639 - 640
  • [28] Micrometastatic node-positive breast cancer in comparison to node-negative and macrometastic node-positive disease: a survival analysis of 9637 women referred to the British Columbia Cancer Agency.
    Truong, P. T.
    Chia, S.
    Li, K.
    Macfarlane, R.
    Lesperance, M.
    Speers, C. H.
    Olivotto, I. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S88 - S88
  • [29] ADJUVANT CHEMOTHERAPY AND ENDOCRINE THERAPY FOR NODE-POSITIVE AND NODE-NEGATIVE BREAST-CARCINOMA
    ALBAIN, KS
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1989, 32 (04): : 835 - 857
  • [30] Quantitative relations of lymph node-positive and node-negative in lower lips epidermoid carcinomas
    Frincu, LL
    Calin, D
    Radulescu, D
    Fatu, AM
    Tudorica, DG
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (04): : S91 - S91